| Previous Close | 1.8800 |
| Open | 1.8800 |
| Bid | 1.7800 x 900 |
| Ask | 1.9800 x 1200 |
| Day's Range | 1.7900 - 1.8800 |
| 52 Week Range | 1.7100 - 4.2100 |
| Volume | 12,313 |
| Avg. Volume | 244,082 |
| Market Cap | 59.601M |
| Beta (3Y Monthly) | 1.84 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Recruitment for 2nd line (PD-1 refractory) NSCLC and 2nd line HNSCC cohorts of the TACTI-002 trial, conducted in collaboration with MSD, are ongoingInitial data from the.
Highlights First patient received first dose in INSIGHT-004, a phase I clinical trialEvaluates the combination of eftilagimod alpha with avelumab (BAVENCIO®) in different.
SYDNEY, Australia, June 03, 2019 -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for.
NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce the grant of a new patent (number 3089749) entitled “Combined Preparations for the Treatment of Cancer” by the European Patent Office. The new patent protects Immutep’s intellectual property relating to combined therapeutic preparations comprising its lead active immunotherapy candidate eftilagimod alpha (“efti” or “IMP321”) and a chemotherapy agent.
Presented at the World Advanced Therapies & Regenerative Medicine Congress & Expo 2019 SYDNEY, Australia, May 17, 2019 -- Immutep Limited (ASX: IMM; NASDAQ: IMMP).
SYDNEY, Australia, May 10, 2019 -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for.
LONDON, UK / ACCESSWIRE / April 8, 2019 / Immutep (NASDAQ: IMMP) presented encouraging data from TACTI-mel Part B and from preclinical studies of its novel LAG-3 agonist at recent scientific conferences. ...
SYDNEY, Australia, March 27, 2019 -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments.
SYDNEY, Australia, March 21, 2019 -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel immunotherapy treatments.
SYDNEY, Australia, March 18, 2019 -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments.
SYDNEY, Australia, March 07, 2019 -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or the Company), a biotechnology company developing novel immunotherapy treatments for.
The First Patient has been dosed at “START Madrid- FJD” in SpainClinical trial sites are active and more will be activated and commence recruitment in coming months SYDNEY,.
SYDNEY, Australia, March 04, 2019 -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or the Company), a biotechnology company developing novel immunotherapy treatments for.
SYDNEY, Australia, Feb. 27, 2019 -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or the Company), a biotechnology company developing novel immunotherapy treatments for.
New clinical trial collaboration with CYTLIMIC to test eftilagimod alpha (“efti” or “IMP321”) as part of a cancer peptide vaccine discovered by artificial intelligenceBuilds on.
NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, today announces it has entered into a securities purchase agreement (the “Purchase Agreement”) with certain accredited investors to purchase 260,000,000 ordinary shares represented by 2,600,000 American Depositary Shares (“ADSs”) at a purchase price per ADS of US$2.00 in a registered direct offering, for total gross proceeds of approximately US$5.2 million (equivalent to A$7.2 million). In a concurrent private placement, the Company has agreed to issue warrants to purchase up to 208,000,000 ordinary shares represented by 2,080,000 ADSs. The warrants will have an exercise price of US$2.50 per ADS and will be exercisable immediately following the close of this private placement and will expire three years from the date of effectiveness of the registration statement registering for resale the ordinary shares underlying the warrants.
SYDNEY, Australia, Nov. 27, 2018 -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), announces new data from its ongoing TACTI-mel Phase I clinical trial.
LONDON, Nov. 22, 2018 -- We expect Immutep (IMMP:US) to deliver on a number of important milestones in the year ahead. The AIPAC Phase II study of its APC activator eftilagimod.
NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, today announced new positive interim data from its TACTI-mel Phase I clinical trial, presented at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Washington, D.C., U.S. The TACTI-mel study is evaluating the use of eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3Ig fusion protein based on the LAG-3 immune control mechanism, in combination with anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for unresectable or metastatic melanoma.
Highlights Site selection process advancing for planned TACTI-002 Phase II trial which will include recruitment of up to 110 patientsAIPAC Phase IIb recruitment reaches 155.